Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
Deep Dive Into Biogen Stock: Analyst Perspectives (17 Ratings)
深入了解百健股票：分析師觀點（17 個評級）
Analysts' ratings for Biogen (NASDAQ:BIIB) over the last quarter vary from bullish to bearish, as provided by 17 analysts.
17位分析師提供的分析師對Biogen（納斯達克股票代碼：BIIB）在上個季度的評級從看漲到看跌不等。
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
下表彙總了他們最近的評級，闡明瞭過去30天內情緒的變化，並將其與前幾個月進行了比較。
The 12-month price targets, analyzed by analysts, offer insights with an average target of $274.41, a high estimate of $364.00, and a low estimate of $200.00. Surpassing the previous average price target of $272.25, the current average has increased by 0.79%.
分析師分析的12個月目標股價提供了見解，平均目標股價爲274.41美元，最高估計爲364.00美元，低估值爲200.00美元。超過了之前的平均目標股價272.25美元，目前的平均價格上漲了0.79％。
Breaking Down Analyst Ratings: A Detailed Examination
分解分析師評級：詳細審查
An in-depth analysis of recent analyst actions unveils how financial experts perceive Biogen...
對分析師近期行爲的深入分析揭...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。